Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Ann Thorac Surg. 2021 Apr;111(4):1316-1324. doi: 10.1016/j.athoracsur.2020.06.083. Epub 2020 Sep 3.
Venous-arterial extracorporeal membrane oxygenation (ECMO) is an established technique for intraoperative cardiopulmonary support in patients undergoing lung transplantation. Patients with pulmonary fibrosis have a higher risk to require it. The aim of this study was to identify risk factors for the need of intraoperative ECMO use.
Records of patients undergoing lung transplantation for pulmonary fibrosis at our institution between January 2010 and May 2018 were retrospectively reviewed. Univariate logistic regression analysis was used for statistical identification of risk factors.
There were 105 patients (34%) who required intraoperative ECMO support (ECMO+ group), and 203 (66%) did not (ECMO- group). Preoperative proof of pulmonary hypertension was identified as a risk factor for intraoperative ECMO support (odds ratio [OR], 3.8; 95% confidence interval [CI], 2.2-6.5; P < .01). Revealed mean pulmonary arterial pressure values exceeding 50 mm Hg and pulmonary vascular resistance values exceeding 9.4 Wood units were identified as risk factors for the need of intraoperative ECMO use with a prediction probability of 70%. Increased recipient body surface area (OR, 0.2; 95% CI, 0.1-0.5; P < .01) emerged as a protective factor against intraoperative ECMO (Hosmer-Lemeshow statistic, P = .71) as well as higher cardiac output (OR, 0.7; 95% CI, 0.6-0.9; P < .01). The postoperative course was more complicated in the ECMO+ group, whereas survival at 5 years did not differ among groups (70% vs 69%, P = .79).
Pulmonary hypertension with elevated pulmonary vascular resistance values predicts the need of intraoperative ECMO in patients receiving lung transplantation for pulmonary fibrosis. Although the postoperative course was more complicated in the ECMO+ group, long-term survival did not differ significantly.
静脉-动脉体外膜肺氧合(ECMO)是一种在接受肺移植的患者中进行术中心肺支持的成熟技术。患有肺纤维化的患者更需要使用它。本研究旨在确定术中需要使用 ECMO 的危险因素。
回顾性分析了 2010 年 1 月至 2018 年 5 月期间我院接受肺纤维化肺移植的患者的记录。采用单因素逻辑回归分析确定危险因素。
105 例(34%)患者需要术中 ECMO 支持(ECMO+组),203 例(66%)患者不需要(ECMO-组)。术前证实存在肺动脉高压是术中 ECMO 支持的危险因素(比值比[OR],3.8;95%置信区间[CI],2.2-6.5;P<0.01)。发现平均肺动脉压超过 50mmHg 和肺血管阻力超过 9.4 伍德单位被确定为需要术中 ECMO 治疗的危险因素,其预测概率为 70%。受体体表面积增加(OR,0.2;95%CI,0.1-0.5;P<0.01)是一种针对术中 ECMO(Hosmer-Lemeshow 统计,P=0.71)的保护因素,而心输出量增加(OR,0.7;95%CI,0.6-0.9;P<0.01)也是一种保护因素。ECMO+组的术后病程更复杂,而各组 5 年生存率无差异(70%vs69%,P=0.79)。
肺血管阻力升高的肺动脉高压预测了肺纤维化患者接受肺移植时术中 ECMO 的需求。尽管 ECMO+组的术后病程更复杂,但长期生存率没有显著差异。